All In Biotech

Drug Trial Radar · NCT02446093

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Neoadjuvant CAN-2409 Plus Prodrug in Combination With Chemoradiation or Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Jan 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

54

Planned (sponsor's estimate)

Start

Oct 2015

Primary completion

Dec 2025

Study completion Jul 2026

Sponsor

Lead sponsor
Candel Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Mayo Clinic
First posted
May 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radiation therapy (SBRT). The Standard of Care (SOC) Control arm will be used as a benchmark for informal comparisons of efficacy, safety, and biomarkers.

Conditions

  • Borderline Resectable Pancreatic Adenocarcinoma

Interventions

  • Aglatimagene besadenovecBiological

    Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.

  • ChemoradiationRadiation

    CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.

  • Stereotactic body radiation therapyRadiation

    SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.

  • SurgeryProcedure

    Surgical resection should be performed within 8 weeks after completing CR or SBRT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety grade by CTCAE version 4.0Time frame: From the time of CAN-2409 administration to 30 days after the last dose of valacyclovir.
  2. Survival RateTime frame: 24 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Lee Health/Regional Cancer Center

    Fort Myers, Florida

  • Ohio State University

    Columbus, Ohio

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.